Title: Virally Encoded RNAs as Substrates, Inhibitors, and Delivery Vehicles for RNAi
Patent Number: 7,776,569
Filed: Aug. 23, 2004
Lead Inventor: Timothy Kowalik, University of Massachusetts
The invention, the patent's abstract states, "provides methods for identifying druggable targets in assays that feature compositions, cells and/or organisms having structured viral non-coding RNAs, and an RNA interference pathway. Methods for identifying antiviral agents and creating vaccines are also featured.
"The invention further provides methods for inhibiting RNAi involving svRNAs or inhibitory derivatives thereof," the abstract notes. "The invention also provides compositions for delivering siRNA and miRNA molecules derived from svRNA loci and methods of use thereof. Therapeutic methods are also featured."
Title: Bioinformatically Detectable Group of Novel Regulatory Viral and Viral-Associated Oligonucleotides and Uses Thereof
Patent Number: 7,777,022
Filed: May 26, 2004
Lead Inventor: Isaac Bentwich, Rosetta Genomics
The invention relates to "a first group of novel viral and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM [oligonucleotides], and a second group of novel operon-like viral and human polynucleotides, here identified as Genomic Record or GR" polynucleotides, the patent's abstract states. "GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various viral diseases.
"Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof," the abstract states.
Title: Method for the Chemical Synthesis of Oligonucleotides
Patent Number: 7,777,023
Filed: Oct. 14, 2005
Lead Inventor: Chandra Vargeese, Sirna Therapeutics
The invention, the patent's abstract states, "features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof."
Title: Targets for Tumor Growth Inhibition
Application Number: 20100203036
Filed: Dec. 29, 2009
Lead Inventor: Patrick Lu, Intradigm
The invention "relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing, and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13, and ZFP236, respectively," the patent application's abstract states. "The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug, and gene therapy modalities, or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 … ICT1031, and ICB1003 that are validated for antibody, small molecule, and other inhibitor drug modalities."
Title: Inhibitors for Growth Hormone and Related Hormones, and Methods of Use Thereof
Application Number: 20100203060
Filed: May 30, 2008 PCT Filed: May 30, 2008
Inventor: Peter Lobie, University of Auckland
The invention, the patent application's abstract states, "encompasses novel inhibitors for growth hormone and related hormones, including prolactin … placental lactogen, and other hormones. The invention specifically encompasses antibodies, antibody fragments, and modifications thereof, as well as polynucleotides, such antisense polynucleotides, interfering RNAs, and small interfering RNAs, and uses thereof, for inhibition of one or more of such hormones.
"In particular aspects, the invention encompasses methods of producing such inhibitors, compositions comprising one or more of these inhibitors, and methods of inhibiting a cell, e.g., inhibiting cell proliferation, cell survival, or cell motility, especially for a cancer cell, using one or more of the inhibitors," it adds. "The invention also encompasses methods of diagnosis and monitoring, and methods of treatment, especially for cancer, using one or more of the disclosed compositions or inhibitors."
Title: Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase for Delivery of Polynucleotides In Vivo
Application Number: 20100203116
Filed: Sept. 24, 2008 PCT Filed: Sept. 24, 2008
Lead Inventor: Marc Mansour, Immunovaccine
"The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject," the patent application's abstract states.
Title: Diagnosis and Treatment of Cancers with microRNA Located In or Near Cancer-Associated Chromosomal Features
Application Number: 20100203544
Filed: March 31, 2010
Lead Inventor: Carlo Croce, Thomas Jefferson University
According to the patent application, "microRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR genes located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject.
"As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal," the application adds, while "microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in [B-cell chronic lymphocytic leukemia] patients provides a means for diagnosing CLL and possibly other cancers."
Title: Two-Color, Real-Time/End-Point Quantitation of microRNAs
Application Number: 20100203545
Filed: April 14, 2010
Lead Inventor: Andrew Finn, Applied Biosystems
The invention is "directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples," the patent application's abstract states. "A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples. In some embodiments, a plurality of small miRNAs are queried with a plurality of linker probes. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions."
Title: Influenza Therapeutic
Application Number: 20100204297
Filed: March 22, 2006 PCT Filed: March 22, 2006
Lead Inventor: Jianzhu Chen, Massachusetts Institute of Technology (Marina Biotech)
The invention, the patent application's abstract states, "provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions.
Further, "the invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences," the abstract continues. "The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention."
Title: Anti-Viral Methods and Compositions
Application Number: 20100204300
Filed: Jan. 16, 2008 PCT Filed: Jan. 16, 2008
Lead Inventor: Stephen Mark Tompkins, University of Georgia
The patent application, its abstract states, "relates to methods and compositions for silencing poxvirus gene expression and replication using RNA interference. In certain embodiments, the disclosure relates to methods of treating a subject with a poxvirus infection."
Title: Small Interfering RNA Molecules Against Ribonucleotide Reductase and Uses Thereof
Application Number: 20100204305
Filed: Feb. 4, 2010
Lead Inventor: Aiping Young, Lorus Therapeutics
The invention, the patent application's abstract states, comprises "small interfering RNA molecules that target a mammalian ribonucleotide reductase gene and which are capable of inhibiting the expression of their target gene. … The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers."
Title: Method of Treating Neurodegenerative Disease
Application Number: 20100204306
Filed: March 16, 2010
Inventor: Pamela Tan, Alnylam Pharmaceuticals
"Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein gene expression, such as for the treatment of neurodegenerative disorders," the patent application's abstract states. "An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells."
Title: Compositions and Methods for Inhibiting Expression of the HAMP Gene
Application Number: 20100204307
Filed: April 9, 2010
Lead Inventor: Tomoko Nakayama, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the HAMP gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by HAMP gene expression, and the expression of the HAMP gene using the pharmaceutical composition."